Komori
Tsubota Laboratory (4890) · InitiativeAdvanced

Development of an innovative medical device for retinitis pigmentosa

First written in FY2024. 4 of 5 entries say "Advanced", first in FY2026-H1. Latest entry: FY2026.

5entries
3years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024AdvancedFY2026-H1 – FY20262024: 120242025: 120252026: 32026
Same theme, other companies
Development of TLG-020 medical device for retinitis pigmentosaA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「A specified clinical trial is currently being conducted for TLG-020, a medical device for retinitis pigmentosa.」

    TLG-020 progressed from the preparation stage for a specified clinical trial to the trial implementation stage.
  3. FY2026-H1AdvancedAnnual report

    「In other ophthalmology fields, preparations continue for a specified clinical trial of the medical device for retinitis pigmentosa, “TLG-020.”」

    The medical device for retinitis pigmentosa was developed as TLG-020 and has progressed to the preparation stage for a specified clinical trial.
  4. FY2024First statedAnnual report

    「“Development of an innovative medical device for retinitis pigmentosa” was selected for a grant under the FY2023 TOKYO Strategic Innovation Promotion Program.」

    Development of a medical device for retinitis pigmentosa was selected for a public grant program and listed as a new research and development theme in posterior segment eye diseases.
Moved together

"Global Out-Licensing and Royalty Monetization of TLM-001, a Treatment for Meibomian Gland Dysfunction" moved the same way as this thread, in the same document, in 4 of its 5 moves.

444333★123456
  1. ★This thread
  2. 1Global Out-Licensing and Royalty Monetization of TLM-001, a Treatment for Meibomian Gland Dysfunction4×
  3. 2Commercialization of R&D Pipelines and Establishment of Post-Launch Royalty Revenue4×
  4. 3Clinical Trial and Launch of TLM-003 Myopia Progression Prevention Eye Drops4×
  5. 4TLG-001 Pivotal Verification Clinical Trial and Medical Device Approval3×
  6. 5Strengthening basic research3×
  7. 6Development and Out-Licensing of TLM-018, a Novel Ophthalmic Drug3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Tsubota Laboratory yet. It last moved in the Results briefing materials of 2026-05-14: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Development of an innovative medical device for retinitis pigmentosa | Tsubota Laboratory Incorporated (4890) | Komori